NEW YORK (Reuters Health) Dec 31 - In men with node-positive prostate cancer, beginning or deferring adjuvant androgen deprivation therapy after surgery does not appear to significantly impact survival, according to a report in the January issue of the Journal of Clinical Oncology.
Dr. Yu-Ning Wong at the Fox Chase Cancer Center in Philadelphia and colleagues came to this conclusion after analyzing Surveillance, Epidemiology and End Results (SEER) and Medicare data on 731 men who underwent radical prostatectomy between 1991 and 1999 and had positive regional lymph nodes.
There was no statistically significant difference in overall survival between the 209 men who received androgen deprivation therapy within 120 days after surgery and the 522 men who did not. There was also no statistically significant survival differences with 90, 150, 180, and 365 days as the adjuvant therapy definition, according to the researchers.
"Our study highlights the significant uncertainty that surrounds the role of adjuvant therapy for men with high-risk, localized prostate cancer," the authors write.
They point out that while androgen deprivation therapy has not been effective when performed prior to prostatectomy, it "has a well-defined role" in patients with locally advanced prostate cancer who are receiving definitive radiation therapy. "This apparent dichotomy may support an interaction between radiation therapy and androgen deprivation therapy," they speculate. "This may also explain the lack of benefit of adjuvant ADT seen in this study."
Dr. Wong and colleagues acknowledge that the findings of this observational study should be validated in a prospective study. Nevertheless, they add, "We believe that these results add to the currently available data and should help treatment decisions, especially in patients who are concerned about androgen deprivation therapy-associated toxicity."
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου